Previous 10 | Next 10 |
2023-09-06 13:16:14 ET More on Viatris Seeking Alpha’s Quant Rating on Viatris Historical earnings data for Viatris Dividend scorecard for Viatris Financial information for Viatris Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs M...
2023-09-05 06:42:18 ET More on Viatris Seeking Alpha’s Quant Rating on Viatris Historical earnings data for Viatris Dividend scorecard for Viatris Financial information for Viatris Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs M...
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV PR Newswire Tentative approval will help enhance access to WHO-recommended paediatric regimen wi...
2023-09-01 08:30:00 ET On Aug. 23, CVS Health (NYSE: CVS) announced that it's launching a new subsidiary focused on biosimilar drugs. That business, Cordavis, will start by seeking to commercialize a biosimilar to AbbVie 's blockbuster Humira. That could mean trouble on the hori...
2023-08-31 08:45:00 ET If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option. Generic drug manufacturers can, in theory, be a reliable source of dividend...
2023-08-28 06:56:00 ET Summary The stock market, specifically the S&P 500, is still lurking over 4,400, up 16% this year. UPS is projecting to earn between $85 billion to $100 billion in revenue, just large amounts, even during a tough year that we have all been through. S...
2023-08-24 17:00:00 ET If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS) . Both companies offer attractive dividends, but which one is a better buy...
2023-08-24 14:12:04 ET More on generic drugmakers Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market Viatris: Turning Point For Cheap Pharma Stock Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain Novartis schedules Sandoz...
2023-08-23 13:35:09 ET More on Viatris Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market Viatris: Turning Point For Cheap Pharma Stock Viatris Q2 2023 Earnings Review: Buy, Sell, Or Hold After Mixed Results? Viatris Inc. ( VTRS ) Q2 2...
2023-08-18 13:09:45 ET Summary On August 7, Viatris released its financial results for the 2nd quarter of 2023, which, after a long time, finally managed to beat analysts' expectations. Viatris' revenue for the second quarter of 2023 was $3.92 billion, up 5.1% from the previous qu...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...
2024-07-15 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...